$2.32
0.43% today
Nasdaq, Apr 03, 06:41 pm CET
ISIN
US7443752057
Symbol
PMDI

Psychemedics Corporation Stock price

$2.33
+0.00 0.08% 1M
+0.03 1.30% 6M
+0.09 4.02% YTD
-0.53 18.53% 1Y
-4.71 66.90% 3Y
-3.33 58.83% 5Y
-14.30 85.99% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.00 0.00%
ISIN
US7443752057
Symbol
PMDI
Sector

Key metrics

Market capitalization $14.24m
Enterprise Value $13.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 15.90
EV/Sales (TTM) EV/Sales 0.71
P/S ratio (TTM) P/S ratio 0.72
P/B ratio (TTM) P/B ratio 2.78
Dividend yield 6.01%
Last dividend (FY23) $0.14
Revenue growth (TTM) Revenue growth -10.92%
Revenue (TTM) Revenue $19.69m
EBIT (operating result TTM) EBIT $-1.89m
Free Cash Flow (TTM) Free Cash Flow $880.00k
Cash position $1.42m
EPS (TTM) EPS $-0.32
Short interest 0.31%
Show more

Is Psychemedics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Psychemedics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Psychemedics Corporation:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Psychemedics Corporation:

Buy
100%

Financial data from Psychemedics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
20 20
11% 11%
100%
- Direct Costs 13 13
8% 8%
64%
7.10 7.10
16% 16%
36%
- Selling and Administrative Expenses 6.16 6.16
18% 18%
31%
- Research and Development Expense 0.75 0.75
34% 34%
4%
0.19 0.19
176% 176%
1%
- Depreciation and Amortization 2.08 2.08
22% 22%
11%
EBIT (Operating Income) EBIT -1.89 -1.89
35% 35%
-10%
Net Profit -1.86 -1.86
55% 55%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Psychemedics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Psychemedics Corporation Stock News

Neutral
GlobeNewsWire
4 months ago
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common ...
Neutral
GlobeNewsWire
5 months ago
DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024.

Company Profile

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.

Head office United States
CEO Brian Hullinger
Employees 101
Founded 1986
Website www.psychemedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today